Nektar Therapeutics
NKTR
$73.32
-$2.12-2.81%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 2.33% | 11.75% | -596.89% | 4.14% | 20.57% |
| Total Depreciation and Amortization | -27.10% | -64.55% | -42.77% | -80.26% | -85.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -261.31% | -66.24% | 85.94% | 63.39% | -133.22% |
| Change in Net Operating Assets | -807.37% | 53.42% | -101.03% | -1,056.26% | -132.97% |
| Cash from Operations | -65.66% | 9.69% | -40.64% | -10.99% | -21.31% |
| Capital Expenditure | -154.05% | -800.00% | -55.77% | 82.88% | 80.11% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -903.63% | -902.84% | -98.21% | -302.55% | 189.21% |
| Cash from Investing | -904.41% | -902.92% | -99.38% | -305.73% | 192.16% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 316.11% | 57,828.57% | 393.98% | 1,730.77% | 1,010.53% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 172,681.52% | 7,564,885.71% | 46,491.57% | 1,089,723.08% | 1,010.53% |
| Foreign Exchange rate Adjustments | -- | -- | -100.00% | 103.57% | 700.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -2,794.46% | 2,609.56% | -283.24% | -190.18% | 119.78% |